Jefferies has retained its buy rating on Zydus Life, while lowering the target price from ₹1,450 to ₹1,380, which still suggests a 45% potential upside from the current market price (CMP) of ₹948.95. The Q2 results showed a positive performance, beating estimates on account of better margins.
Despite the erosion in Asacol HD sales, the outlook for Zydus Life in the U.S. remains strong. The company also continues to demonstrate robust growth in India. Jefferies maintains a high-risk, high-reward stance with its buy rating on the stock.
Disclaimer: This article is for informational purposes only and should not be considered as financial advice. Please consult a financial advisor before making any investment decisions.
